公开(公告)号：US12110283B2

公开(公告)日：2024-10-08

申请号：US17372029

申请日：2021-07-09

申请人： VisEn Medical, Inc.

发明人： Kevin Groves ,  Bagna Bao

IPC分类号： C07D401/06 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K49/00 ,  C07D209/14 ,  C07D209/60 ,  C07D401/14 ,  C07D417/14 ,  C09B23/01 ,  C09B23/08 ,  G01N21/64 ,  G01N33/58

CPC分类号： C07D401/06 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K49/0002 ,  A61K49/0032 ,  A61K49/0052 ,  C07D209/14 ,  C07D209/60 ,  C07D401/14 ,  C07D417/14 ,  C09B23/0008 ,  C09B23/0033 ,  C09B23/083 ,  C09B23/086 ,  G01N21/6458 ,  G01N33/582 ,  G01N2333/988 ,  Y02A50/30

摘要： The invention provides agents that target carbonic anhydrase, which can be used as imaging agents or therapeutic agents. The agents can be used to image tumor hypoxia as well as other physiological processes in a subject.

公开(公告)号：US12083187B2

公开(公告)日：2024-09-10

申请号：US16958636

申请日：2018-12-28

申请人： Wayne State University

发明人： Samaresh Sau ,  Arun K. Iyer ,  Hashem Alsaab

IPC分类号： A61K47/69 ,  A61K47/55 ,  A61K49/00 ,  A61P35/00

CPC分类号： A61K47/6935 ,  A61K47/551 ,  A61K47/6911 ,  A61K49/0045 ,  A61K49/0052 ,  A61K49/0084 ,  A61K49/0093 ,  A61P35/00

摘要： Advancements in solid tumor (e.g., renal cell carcinoma) treatments and imaging are described. The advancements are based on nanoformulations that: (i) overcome deliverability issues associated with anti-cancer compounds; (ii) have increased targeted delivery to tumors, and hypoxic cores of tumors due to the presence of targeting ligands; (iii) have increased delivery to the hypoxic cores of tumors due to engineered shapes; (iv) provide synergistic treatment combinations; and/or (v) overcome cancer cell resistance to therapeutic treatments.

公开(公告)号：US20240285807A1

公开(公告)日：2024-08-29

申请号：US18631340

申请日：2024-04-10

申请人： ON TARGET LABORATORIES, LLC.

发明人： Sumith A. Kularatne

IPC分类号： A61K49/00 ,  A61K9/08 ,  A61K47/02 ,  A61P35/00 ,  A61P41/00

CPC分类号： A61K49/0052 ,  A61K9/08 ,  A61K47/02 ,  A61K49/0032 ,  A61P35/00 ,  A61P41/00

摘要： A composition is configured to be administered to a subject undergoing a malignant lesion resection procedure. The composition comprises a pharmaceutically effective amount of pafolacianine or a pharmaceutically acceptable salt thereof. The pafolacianine or a pharmaceutically acceptable salt thereof is configured to bind one or more malignant lesions and emit an optical signal.

公开(公告)号：US20240173418A1

公开(公告)日：2024-05-30

申请号：US18284035

申请日：2022-03-23

申请人： The Regents of the University of Michigan

发明人： James J. Moon ,  Xiaoqi Sun

IPC分类号： A61K47/54 ,  A61K45/06 ,  A61K49/00 ,  A61K49/08 ,  A61K49/10 ,  A61K51/04

CPC分类号： A61K47/549 ,  A61K45/06 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/085 ,  A61K49/10 ,  A61K51/0491

摘要： This invention is in the field of medicinal chemistry and relates to a new class of cyclic dinucleotide conjugates (e.g., Formula I) which function as tumor-targeted imaging agents, and their use in diagnostic and therapeutic intervention for disorders (e.g., cancer).

公开(公告)号：US20240091315A1

公开(公告)日：2024-03-21

申请号：US18182954

申请日：2023-03-13

申请人： AMUNIX PHARMACEUTICALS, INC.

发明人： Volker Schellenberger ,  Vladimir Podust ,  Chia-Wei Wang ,  Bryant McLaughlin ,  Bee-Cheng Sim ,  Sheng Ding ,  Chen Gu

IPC分类号： A61K38/24 ,  A61K47/64 ,  A61K49/00 ,  C07K5/02

CPC分类号： A61K38/24 ,  A61K47/64 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/0056 ,  C07K5/0205

摘要： The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.

公开(公告)号：US11904025B2

公开(公告)日：2024-02-20

申请号：US17047748

申请日：2019-04-16

申请人： Northwestern University ,  King Abdulaziz City for Science and Technology (KACST)

发明人： Indranil Roy ,  James Fraser Stoddart

IPC分类号： A61B5/00 ,  A61B8/00 ,  A61B10/00 ,  A61K49/00

CPC分类号： A61K49/0052 ,  A61K49/0021

摘要： Described herein are cyclophanes, compositions, and methods for live cell imaging. The cyclophanes comprise an ordered, cyclic arrangement of a chromophore, a first linker unit, a molecular strut, and a second linker unit. The compositions are capable of being taking up by cells and resist photobleaching under live-cell imaging conditions.

公开(公告)号：US20240018208A1

公开(公告)日：2024-01-18

申请号：US18343689

申请日：2023-06-28

申请人： Janssen Pharmaceutica NV

发明人： Mark MACIELAG ,  Raymond J. PATCH ,  Rui ZHANG ,  Martin A. CASE ,  Mark J. WALL ,  Yue-Mei ZHANG

IPC分类号： C07K14/575 ,  A61K47/68 ,  C07K16/24 ,  A61K9/00 ,  A61K38/17 ,  A61K38/26 ,  C07K1/06 ,  C07K1/107 ,  A61K47/64 ,  A61P3/10 ,  A61K49/00 ,  C07K1/12 ,  C07K1/18 ,  C07K5/02 ,  A61K47/60 ,  A61P3/08 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61K38/22 ,  A61K45/06 ,  C07K16/00

CPC分类号： C07K14/575 ,  A61K47/6845 ,  C07K16/24 ,  A61K47/68 ,  A61K47/6883 ,  A61K9/0019 ,  A61K38/1709 ,  A61K38/26 ,  C07K1/061 ,  C07K1/1072 ,  C07K14/57545 ,  A61K47/64 ,  A61P3/10 ,  A61K38/17 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/0056 ,  C07K1/12 ,  C07K1/18 ,  C07K5/0205 ,  A61K47/60 ,  A61P3/08 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61K38/22 ,  A61K45/06 ,  A61K47/6811 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/33 ,  A61K38/00

摘要： The present invention comprises compounds of Formula I.






wherein:
Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.

公开(公告)号：US20230405131A1

公开(公告)日：2023-12-21

申请号：US18251188

申请日：2021-10-29

申请人： INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY

发明人： Seong Young Kwon ,  Jung-Joon Min ,  Yeongjin Hong ,  Sung-Hwan You ,  Dong-Yeon Kim ,  Jin Hee IM

IPC分类号： A61K47/54 ,  A61K49/00 ,  A61K47/66 ,  C12N1/20 ,  C12N15/70

CPC分类号： A61K47/557 ,  A61K49/0052 ,  A61K49/0097 ,  A61K47/665 ,  C12N1/20 ,  C12N15/70 ,  C12N2800/101

摘要： The present invention relates to host cells expressing monomeric streptavidin. The host cells according to the present invention may express streptavidin in vivo, making it possible to visualize and monitor in real time the biodistribution of cancer tissue, pre-targeted by the host cell, with a biotinylated diagnostic agent, as well as to increase the cancer-targeting efficiency of biotinylated anticancer drugs.

公开(公告)号：US20230365644A1

公开(公告)日：2023-11-16

申请号：US18154020

申请日：2023-01-12

申请人： Janssen Pharmaceutica NV

发明人： Mark MACIELAG ,  Raymond J. PATCH ,  Rui ZHANG ,  Martin A. CASE ,  Shamina M. RANGWALA ,  James N. LEONARD ,  Raul C. CAMACHO ,  Michael J. HUNTER ,  Katharine E. D'AQUINO ,  Wilson EDWARDS ,  Ronald V. SWANSON ,  Wenying JIAN ,  Yue-Mei ZHANG ,  Mark WALL ,  Ellen CHI

IPC分类号： C07K14/575 ,  A61K47/68 ,  C07K16/24 ,  A61K9/00 ,  A61K38/17 ,  A61K38/26 ,  C07K1/06 ,  C07K1/107 ,  A61K47/64 ,  A61P3/10 ,  A61K49/00 ,  C07K1/12 ,  C07K1/18 ,  C07K5/02 ,  A61K47/60 ,  A61P3/08 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61K38/22 ,  A61K45/06 ,  C07K16/00

CPC分类号： C07K14/575 ,  A61K47/6845 ,  C07K16/24 ,  A61K47/68 ,  A61K47/6883 ,  A61K9/0019 ,  A61K38/1709 ,  A61K38/26 ,  C07K1/061 ,  C07K1/1072 ,  C07K14/57545 ,  A61K47/64 ,  A61P3/10 ,  A61K38/17 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/0056 ,  C07K1/12 ,  C07K1/18 ,  C07K5/0205 ,  A61K47/60 ,  A61P3/08 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61K38/22 ,  A61K45/06 ,  A61K47/6811 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/33 ,  A61K38/00

摘要： The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.

公开(公告)号：US20230346982A1

公开(公告)日：2023-11-02

申请号：US17661305

申请日：2022-04-29

申请人： Peking University Third Hospital ,  Ordos Clinical Medical College of Inner Mongolia Medical University

发明人： Shumin WANG ,  Xiaolong LIANG ,  Duo ZHAO ,  Shiyuan YANG ,  Menghong XU ,  Huiwen LI

IPC分类号： A61K49/00

CPC分类号： A61K49/0002 ,  A61K49/0052

摘要： The present disclosure provides a fluorescent contrast agent with a targeting function, and a preparation method and a use thereof, and belongs to the technical fields of nanomaterials and biomedical materials. The fluorescent contrast agent (MR780 NPs) of the present disclosure can specifically bind to CD206 on a surface of tumor-associated macrophages (TAMs). MR780 NPs accumulate in lymph nodes invaded by tumor cells and undergo an oxidation-reduction reaction with reduced glutathione in a tumor microenvironment, which triggers a fluorescence signal of MR780 NPs; and MR780 NPs do not accumulate and do not show fluorescence in normal lymph nodes. Therefore, the fluorescent contrast agent of the present disclosure can be used to diagnose lymph node metastasis (LNM) of breast cancer, realize the preoperative evaluation of LNM, assist in the clinical determination of tumor staging and the formulation of a surgical plan, and achieve the accurate resection under intraoperative fluorescence navigation.